(CLDX) Celldex Therapeutics - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.076m | Total Return 51.7% in 12m
Stock: Antibodies, Therapeutics, Inflammation, Autoimmune
Total Rating 29
Risk 31
Buy Signal -1.07
| Risk 5d forecast | |
|---|---|
| Volatility | 57.2% |
| Relative Tail Risk | -9.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 42.03 |
| Character TTM | |
|---|---|
| Beta | 1.000 |
| Beta Downside | 0.990 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.84% |
| CAGR/Max DD | -0.08 |
EPS (Earnings per Share)
Revenue
Description: CLDX Celldex Therapeutics March 05, 2026
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for inflammatory, allergic, and autoimmune diseases. The biotechnology sector is characterized by high research and development costs and a long drug development pipeline.
The companys pipeline includes Barzolvolimab (CDX-0159), a monoclonal antibody targeting the KIT receptor for chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. It also features CDX-622, a bispecific antibody for inflammatory diseases, which targets thymic stromal lymphopoietin and depletes mast cells.
The business model relies on the discovery, development, and commercialization of novel drug candidates. For further insights into their clinical trial progress and market potential, consider exploring ValueRay.
Headlines to watch out for
- Barzolvolimab clinical trial results impact stock
- Regulatory approval for CDX-0159 drives valuation
- Competition in mast cell disease market affects revenue
- Pipeline development for inflammatory diseases influences future growth
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -258.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA -16.59 > 1.0 |
| NWC/Revenue: 32.2k% < 20% (prev 10.1k%; Δ 22.2k% < -1%) |
| CFO/TA -0.36 > 3% & CFO -210.9m > Net Income -258.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.5m) vs 12m ago 0.22% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.22% > 50% (prev 0.89%; Δ -0.67% > 0%) |
| Interest Coverage Ratio: -12.36 > 6 (EBITDA TTM -278.2m / Interest Expense TTM -22.8m) |
Altman Z'' -15.00
| A: 0.83 (Total Current Assets 534.7m - Total Current Liabilities 51.0m) / Total Assets 583.0m |
| B: -3.11 (Retained Earnings -1.81b / Total Assets 583.0m) |
| C: -0.41 (EBIT TTM -281.6m / Avg Total Assets 687.7m) |
| D: -32.43 (Book Value of Equity -1.81b / Total Liabilities 55.8m) |
| Altman-Z'' Score: -41.51 = D |
Beneish M 1.00
| DSRI: 13.47 (Receivables 2.02m/700k, Revenue 1.50m/7.02m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.49 (AQ_t 0.07 / AQ_t-1 0.05) |
| SGI: 0.21 (Revenue 1.50m / 7.02m) |
| TATA: -0.08 (NI -258.8m - CFO -210.9m) / TA 583.0m) |
| Beneish M-Score: 6.88 (Cap -4..+1) = D |
What is the price of CLDX shares?
As of March 29, 2026, the stock is trading at USD 30.30 with a total of 876,090 shares traded.
Over the past week, the price has changed by -1.94%, over one month by +0.70%, over three months by +16.40% and over the past year by +51.65%.
Over the past week, the price has changed by -1.94%, over one month by +0.70%, over three months by +16.40% and over the past year by +51.65%.
Is CLDX a buy, sell or hold?
Celldex Therapeutics has received a consensus analysts rating of 4.57.
Therefore, it is recommended to buy CLDX.
- StrongBuy: 10
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.3 | 79.3% |
| Analysts Target Price | 54.3 | 79.3% |
CLDX Fundamental Data Overview March 26, 2026
P/S = 1343.8215
P/B = 3.9018
Revenue TTM = 1.50m USD
EBIT TTM = -281.6m USD
EBITDA TTM = -278.2m USD
Long Term Debt = 2.34m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.55m USD (from shortTermDebt, last quarter)
Debt = 2.34m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.56b USD (2.08b + Debt 2.34m - CCE 518.6m)
Interest Coverage Ratio = -12.36 (Ebit TTM -281.6m / Interest Expense TTM -22.8m)
EV/FCF = -7.31x (Enterprise Value 1.56b / FCF TTM -213.4m)
FCF Yield = -13.68% (FCF TTM -213.4m / Enterprise Value 1.56b)
FCF Margin = -14.2k% (FCF TTM -213.4m / Revenue TTM 1.50m)
Net Margin = -17.3k% (Net Income TTM -258.8m / Revenue TTM 1.50m)
Gross Margin = unknown ((Revenue TTM 1.50m - Cost of Revenue TTM 62.9m) / Revenue TTM)
Tobins Q-Ratio = 2.68 (Enterprise Value 1.56b / Total Assets 583.0m)
Interest Expense / Debt = 133.1% (Interest Expense 3.11m / Debt 2.34m)
Taxrate = 21.0% (US default 21%)
NOPAT = -222.4m (EBIT -281.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.49 (Total Current Assets 534.7m / Total Current Liabilities 51.0m)
Debt / Equity = 0.00 (Debt 2.34m / totalStockholderEquity, last quarter 527.2m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -26.5m / EBITDA -278.2m)
Debt / FCF = 0.12 (negative FCF - burning cash) (Net Debt -26.5m / FCF TTM -213.4m)
Total Stockholder Equity = 621.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.63% (Net Income -258.8m / Total Assets 583.0m)
RoE = -41.68% (Net Income TTM -258.8m / Total Stockholder Equity 621.0m)
RoCE = -45.17% (EBIT -281.6m / Capital Employed (Equity 621.0m + L.T.Debt 2.34m))
RoIC = -35.82% (negative operating profit) (NOPAT -222.4m / Invested Capital 621.0m)
WACC = 9.49% (E(2.08b)/V(2.08b) * Re(9.50%) + (debt cost/tax rate unavailable))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.06%
[DCF] Fair Price = unknown (Cash Flow -213.4m)
EPS Correlation: -76.51 | EPS CAGR: -48.81% | SUE: -2.51 | # QB: 0
Revenue Correlation: 2.53 | Revenue CAGR: -20.10% | SUE: -0.76 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.22 | Chg7d=-0.122 | Chg30d=-0.131 | Revisions Net=-5 | Analysts=10
EPS current Year (2026-12-31): EPS=-4.77 | Chg7d=-0.434 | Chg30d=-0.357 | Revisions Net=-7 | Growth EPS=-22.4% | Growth Revenue=+121.5%
EPS next Year (2027-12-31): EPS=-4.73 | Chg7d=-0.006 | Chg30d=+0.157 | Revisions Net=-3 | Growth EPS=+0.8% | Growth Revenue=+214.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)
P/B = 3.9018
Revenue TTM = 1.50m USD
EBIT TTM = -281.6m USD
EBITDA TTM = -278.2m USD
Long Term Debt = 2.34m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.55m USD (from shortTermDebt, last quarter)
Debt = 2.34m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.56b USD (2.08b + Debt 2.34m - CCE 518.6m)
Interest Coverage Ratio = -12.36 (Ebit TTM -281.6m / Interest Expense TTM -22.8m)
EV/FCF = -7.31x (Enterprise Value 1.56b / FCF TTM -213.4m)
FCF Yield = -13.68% (FCF TTM -213.4m / Enterprise Value 1.56b)
FCF Margin = -14.2k% (FCF TTM -213.4m / Revenue TTM 1.50m)
Net Margin = -17.3k% (Net Income TTM -258.8m / Revenue TTM 1.50m)
Gross Margin = unknown ((Revenue TTM 1.50m - Cost of Revenue TTM 62.9m) / Revenue TTM)
Tobins Q-Ratio = 2.68 (Enterprise Value 1.56b / Total Assets 583.0m)
Interest Expense / Debt = 133.1% (Interest Expense 3.11m / Debt 2.34m)
Taxrate = 21.0% (US default 21%)
NOPAT = -222.4m (EBIT -281.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.49 (Total Current Assets 534.7m / Total Current Liabilities 51.0m)
Debt / Equity = 0.00 (Debt 2.34m / totalStockholderEquity, last quarter 527.2m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -26.5m / EBITDA -278.2m)
Debt / FCF = 0.12 (negative FCF - burning cash) (Net Debt -26.5m / FCF TTM -213.4m)
Total Stockholder Equity = 621.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.63% (Net Income -258.8m / Total Assets 583.0m)
RoE = -41.68% (Net Income TTM -258.8m / Total Stockholder Equity 621.0m)
RoCE = -45.17% (EBIT -281.6m / Capital Employed (Equity 621.0m + L.T.Debt 2.34m))
RoIC = -35.82% (negative operating profit) (NOPAT -222.4m / Invested Capital 621.0m)
WACC = 9.49% (E(2.08b)/V(2.08b) * Re(9.50%) + (debt cost/tax rate unavailable))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.06%
[DCF] Fair Price = unknown (Cash Flow -213.4m)
EPS Correlation: -76.51 | EPS CAGR: -48.81% | SUE: -2.51 | # QB: 0
Revenue Correlation: 2.53 | Revenue CAGR: -20.10% | SUE: -0.76 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.22 | Chg7d=-0.122 | Chg30d=-0.131 | Revisions Net=-5 | Analysts=10
EPS current Year (2026-12-31): EPS=-4.77 | Chg7d=-0.434 | Chg30d=-0.357 | Revisions Net=-7 | Growth EPS=-22.4% | Growth Revenue=+121.5%
EPS next Year (2027-12-31): EPS=-4.73 | Chg7d=-0.006 | Chg30d=+0.157 | Revisions Net=-3 | Growth EPS=+0.8% | Growth Revenue=+214.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)